Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,823 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Randomized safety and immunogenicity trial of a seasonal trivalent inactivated split virion influenza vaccine (IVACFLU-S) in healthy young Vietnamese adults.
Anh DD, Thiem VD, Anh NTH, Huong VM, Nga NT, Thang TC, Thai DH, Chien VC, Holt R, Wahid R, Flores J, Berlanda Scorza F, Taylor DN. Anh DD, et al. Among authors: holt r. Vaccine. 2016 Oct 26;34(45):5457-5462. doi: 10.1016/j.vaccine.2016.08.052. Epub 2016 Aug 24. Vaccine. 2016. PMID: 27567493 Free article. Clinical Trial.
Safety and immunogenicity of a seasonal trivalent inactivated split influenza vaccine: a phase I randomized clinical trial in healthy Serbian adults.
Stevanovic G, Lavadinovic L, Filipovic Vignjevic S, Holt R, Ilic K, Berlanda Scorza F, Sparrow E, Stoiljkovic V, Torelli G, Madenwald T, Socquet M, Barac A, Ilieva-Borisova Y, Pelemis M, Flores J. Stevanovic G, et al. Among authors: holt r. Hum Vaccin Immunother. 2018 Mar 4;14(3):579-586. doi: 10.1080/21645515.2017.1415683. Epub 2018 Feb 23. Hum Vaccin Immunother. 2018. PMID: 29239682 Free PMC article. Clinical Trial.
A Phase 2/3 double blinded, randomized, placebo-controlled study in healthy adult participants in Vietnam to examine the safety and immunogenicity of an inactivated whole virion, alum adjuvanted, A(H5N1) influenza vaccine (IVACFLU-A/H5N1).
Duong TN, Thiem VD, Anh DD, Cuong NP, Thang TC, Huong VM, Chien VC, Phuong NTL, Montomoli E, Holt R, Scorza FB, Flores J, Tewari T. Duong TN, et al. Among authors: holt r. Vaccine. 2020 Feb 5;38(6):1541-1550. doi: 10.1016/j.vaccine.2019.11.059. Epub 2019 Dec 4. Vaccine. 2020. PMID: 31812464 Free article. Clinical Trial.
A phase 2 randomized controlled dose-ranging trial of recombinant pertussis booster vaccines containing genetically inactivated pertussis toxin in women of childbearing age.
Chokephaibulkit K, Puthanakit T, Bhat N, Mansouri S, Tang Y, Lapphra K, Rungmaitree S, Anugulruengkitt S, Jantarabenjakul W, Andi-Lolo I, Holt R, Fortuna L, Kerdsomboon C, Chinwangso P, Suwitruengrit L, van den Biggelaar AHJ, Viviani S, Pham HT, Innis BL. Chokephaibulkit K, et al. Among authors: holt r. Vaccine. 2022 Apr 1;40(15):2352-2361. doi: 10.1016/j.vaccine.2021.10.076. Epub 2021 Nov 14. Vaccine. 2022. PMID: 34789403 Free PMC article. Clinical Trial.
A phase 2 randomized controlled dose-ranging trial of recombinant pertussis booster vaccines containing genetically inactivated pertussis toxin in pregnant women.
Puthanakit T, Chokephaibulkit K, Chaithongwongwatthana S, Bhat N, Tang Y, Anugulruengkitt S, Chayachinda C, Anuwutnavin S, Lapphra K, Rungmaitree S, Tawan M, Andi-Lolo I, Holt R, Fortuna L, Kerdsomboon C, Yuwaree V, Mansouri S, Thai PH, Innis BL. Puthanakit T, et al. Among authors: holt r. Vaccine. 2023 Jul 12;41(31):4541-4553. doi: 10.1016/j.vaccine.2023.06.001. Epub 2023 Jun 15. Vaccine. 2023. PMID: 37330371 Free PMC article. Clinical Trial.
Effective and safe transfer of maternal antibodies persisting two months postpartum following maternal immunization with different doses of recombinant pertussis-containing vaccines.
Chokephaibulkit K, Puthanakit T, Chaithongwongwatthana S, Bhat N, Tang Y, Anugulruengkitt S, Chayachinda C, Anuwutnavin S, Lapphra K, Rungmaitree S, Tawan M, Andi-Lolo I, Holt R, Fortuna L, Kerdsomboon C, Yuwaree V, Mansouri S, Thai PH, Innis BL. Chokephaibulkit K, et al. Among authors: holt r. Vaccine. 2024 Jan 12;42(2):383-395. doi: 10.1016/j.vaccine.2023.11.042. Epub 2023 Dec 7. Vaccine. 2024. PMID: 38061956 Free PMC article.
HIV vaccine-induced sero-reactivity: a challenge for trial participants, researchers, and physicians.
VISR Working Group of Global HIV Vaccine Enterprise; Voronin Y, Zinszner H, Karg C, Brooks K, Coombs R, Hural J, Holt R, Fast P, Allen M. VISR Working Group of Global HIV Vaccine Enterprise, et al. Among authors: holt r. Vaccine. 2015 Mar 3;33(10):1243-9. doi: 10.1016/j.vaccine.2014.10.040. Epub 2015 Jan 31. Vaccine. 2015. PMID: 25649349 Free PMC article. Review.
1,823 results